6,498 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Purchased by Contravisory Investment Management Inc.

Contravisory Investment Management Inc. acquired a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 6,498 shares of the company’s stock, valued at approximately $251,000.

Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in shares of Protagonist Therapeutics by 749.2% during the 3rd quarter. GAMMA Investing LLC now owns 552 shares of the company’s stock valued at $25,000 after buying an additional 487 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in Protagonist Therapeutics in the fourth quarter worth $38,000. Exchange Traded Concepts LLC bought a new position in shares of Protagonist Therapeutics during the third quarter worth about $43,000. CWM LLC increased its holdings in shares of Protagonist Therapeutics by 910.3% in the 3rd quarter. CWM LLC now owns 1,273 shares of the company’s stock worth $57,000 after acquiring an additional 1,147 shares during the period. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Protagonist Therapeutics in the 3rd quarter worth about $69,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on PTGX shares. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Protagonist Therapeutics in a research report on Tuesday, December 10th. TD Cowen upgraded shares of Protagonist Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 25th. The Goldman Sachs Group assumed coverage on Protagonist Therapeutics in a research note on Friday, December 6th. They set a “neutral” rating and a $47.00 price target for the company. BMO Capital Markets began coverage on shares of Protagonist Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $62.00 price target on the stock. Finally, Wedbush restated an “outperform” rating and set a $58.00 price target on shares of Protagonist Therapeutics in a report on Tuesday, November 19th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.78.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ PTGX opened at $36.54 on Friday. The firm has a 50 day moving average price of $40.74 and a 200 day moving average price of $41.61. Protagonist Therapeutics, Inc. has a 52-week low of $23.17 and a 52-week high of $48.89. The stock has a market cap of $2.18 billion, a P/E ratio of 13.74 and a beta of 2.23.

Insider Transactions at Protagonist Therapeutics

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 1,906 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $40.98, for a total value of $78,107.88. Following the sale, the insider now owns 46,444 shares in the company, valued at $1,903,275.12. This represents a 3.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Dinesh V. Ph D. Patel sold 78,520 shares of Protagonist Therapeutics stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $46.96, for a total transaction of $3,687,299.20. Following the sale, the chief executive officer now directly owns 435,208 shares of the company’s stock, valued at $20,437,367.68. The trade was a 15.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 209,863 shares of company stock valued at $9,689,847 over the last 90 days. 5.40% of the stock is owned by corporate insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.